Birmingham, West Midlands — (TechSonian) — 15/05/2014 — Nuvilex, (OTCMKTS:NVLX), announced that world renowned oncologist and gastroenterologist Professor Dr. Matthias Lohr of the famed Karolinska Institute in Stockholm, Sweden, has agreed to play a major role in Nuvilex’s Phase 2b clinical trial in pancreatic cancer to be conducted in Australia, as well as other clinical studies and trials in which Nuvilex will be involved.
Nuvilex Inc (OTCMKTS:NVLX) opened the session at $0.32, trading in a range of $0.316 to $0.318, and closed at $0.316. The stock showed a negative performance of -0.47% in the last trading session. The stock traded on a volume of 0.254 million shares and the average volume of the stock remained 5.49 million shares.
Has NVLX Found The Bottom and Ready To Move Up? Find Out Here
mCig Inc (OTCBB:MCIG) has updated its investor presentation for the month of April 2014. This presentation also known as an “Investor Deck” summarizes the most recent developments and performance metrics to existing investors, potential investors, and potential combined venture partners and brand ambassadors.
mCig Inc (OTCBB:MCIG) traded 0.285 million shares in the last business day while the average volume of the stock remained 3.44 million shares. The stock showed a negative movement of -3.81% to end at $0.404. The 52 week range of the stock remained $0.01 to $0.92.
Has MCIG Found The Bottom And Ready To Gain Momentum? Find Out Here
Digital Caddies, (OTCMKTS:CADY), a leader in on-course delivery of technology services and content to golfers, is pleased to announce the addition of LiveRail to their advertising platform.
DIGITAL CADDIES INC (OTCMKTS:CADY)reported 0.351 million shares were exchanged during the last trade, while the average volume is about 0.280 million shares. The stock dropped -1.87% and finished the day at $0.420. The beta of the stock is recorded at -1.53.
Why Should Investors Buy CADY After the Recent Fall? Just Go Here and Find Out
Elite Pharmaceuticals Inc (OTCBB:ELTP) declared the expansion of intellectual property protection surrounding the Company’s abuse prevention technology with the issuance of Canadian Patent Number 2,521,655 titled “Abuse-Resistant Oral Dosage Forms and Method of Use Thereof.
Elite Pharmaceuticals Inc (OTCBB:ELTP) the stockdecreased -3.33% and finished the session at $0.449. Traded with volume of 1.10 million shares in the prior session and the average volume of the stock remained 2.21 million shares.
Will ELTP Get Buyers Even After The Recent Decline? Find Out Here
This entry passed through the Full-Text RSS service — if this is your content and you’re reading it on someone else’s site, please read the FAQ at fivefilters.org/content-only/faq.php#publishers.